Amplyx, now a subsidiary of Pfizer Inc.

Amplyx, **founded in 2006**, is a biotechnology and pharmaceutical company that aims to **save lives** by developing a new class of antifungal medicine, addressing the limitations of current therapeutic options. Their focus is on developing first-in-class products for the treatment of life-threatening infections, with an initial emphasis on deadly fungal pathogens in vulnerable, immune-compromised patients. The company's leadership possesses **extensive experience** in drug development for infectious diseases and rare conditions. Amplyx recently received a significant **$53.00M Series C investment on 19 May 2020**, with participation from notable investors such as **New Enterprise Associates, RiverVest, Sofinnova Investments, Pappas Capital, Adage Capital Management, Arix Bioscience, Lundbeckfonden Ventures, Pfizer, BioMed Ventures**, and **3×5 Partners**. As of now, **Pfizer Inc.** has acquired Amplyx, positioning the company to potentially make a greater impact in the field. For more information, visit their website at **www.amplyx.com**.